Martin Marino Purchases 69,000 Shares of Microbix Biosystems (TSE:MBX) Stock

Microbix Biosystems Inc. (TSE:MBX) Director Martin Marino acquired 69,000 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was acquired at an average cost of C$0.26 per share, for a total transaction of C$17,940.00. Following the transaction, the director owned 1,860,667 shares of the company’s stock, valued at C$483,773.42. This represents a 3.85% increase in their ownership of the stock.

Martin Marino also recently made the following trade(s):

• On Thursday, May 28th, Martin Marino acquired 115,000 shares of Microbix Biosystems stock. The stock was acquired at an average cost of C$0.28 per share, for a total transaction of C$32,200.00.
• On Wednesday, May 27th, Martin Marino acquired 24,500 shares of Microbix Biosystems stock. The stock was acquired at an average cost of C$0.26 per share, for a total transaction of C$6,370.00.

Microbix Biosystems Stock Performance

Shares of MBX stock opened at C$0.27 on Friday. The company’s fifty day simple moving average is C$0.24 and its 200-day simple moving average is C$0.24. The company has a quick ratio of 5.57, a current ratio of 5.35 and a debt-to-equity ratio of 27.03. The firm has a market cap of C$37.13 million, a PE ratio of -6.59 and a beta of 0.48. Microbix Biosystems Inc. has a 12 month low of C$0.21 and a 12 month high of C$0.34.

Microbix Biosystems (TSE:MBX) last announced its quarterly earnings data on Thursday, May 14th. The company reported C($0.01) EPS for the quarter. The business had revenue of C$3.38 million during the quarter. Microbix Biosystems had a negative return on equity of 21.02% and a negative net margin of 38.62%. Equities research analysts expect that Microbix Biosystems Inc. will post 0.02 EPS for the current fiscal year.

About Microbix Biosystems

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.